Intensity Therapeutics, Inc. (INTS) AI Stock Analysis

• Market Cap: $25.53M
• Dividend Yield: N/A
• Average Volume (3M): 5.11M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.53
• Revenue Growth: N/A
• EPS Growth: 46.41%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 60,064,964
• 10 Day Avg. Volume: 8,790,984
• 30 Day Avg. Volume: 5,112,980
• PEG Ratio: 0.10
• Price to Book (P/B): 8.39
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.61
• Enterprise Value/Market Cap: 0.15
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.40
• 1Y Price Target: $3.33
• Price Target Upside: 693.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.41 ▼(-2.86% Downside)

The score is primarily constrained by weak financial performance (no meaningful revenue, ongoing losses, and material cash burn indicating continued reliance on external funding). Technicals also weigh on the score with bearish trend signals (below short-term moving averages and negative MACD). Valuation is neutral-to-weak because a negative P/E limits comparability and there is no dividend yield support.

Positive Factors

Low Debt Levels

The company's low debt levels reduce financial risk and provide flexibility, allowing management to focus on strategic growth initiatives without the burden of high-interest obligations.

Clinical Progress

Positive clinical trial results for INT230-6 enhance the company's prospects in oncology, potentially leading to successful product development and future revenue streams.

Extended Cash Runway

The extended cash runway provides financial stability, allowing the company to continue its R&D efforts and clinical trials without immediate pressure to secure additional funding.

Negative Factors

No Revenue Stream

Lack of a revenue stream limits financial self-sufficiency, making the company heavily reliant on external funding, which could impact long-term sustainability if capital markets tighten.

Cash Burn

Significant cash burn indicates ongoing operational losses, necessitating continuous external financing, which could be challenging if investor sentiment shifts or market conditions worsen.

Nasdaq Compliance Risk

Failure to meet Nasdaq listing requirements could lead to delisting, adversely affecting the company's market perception and access to capital, which are crucial for its ongoing operations.

Intensity Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

How the Company Makes Money

Intensity Therapeutics, Inc. generates revenue primarily through partnerships, collaborations, and licensing agreements with pharmaceutical companies and research institutions. As a clinical-stage company, its revenue model is heavily reliant on securing funding through strategic alliances and collaborations that support its research and development activities. Additionally, the company may receive milestone payments and royalties upon successful commercialization of its therapies developed in collaboration with its partners. The company's financial success is contingent on the advancement of its drug candidates through clinical trials and eventual regulatory approval, which would enable it to license or co-develop its proprietary treatments with larger pharmaceutical companies.

Intensity Therapeutics, Inc. Financial Statement Overview

Summary

Intensity Therapeutics is in its development phase, typical of biotechnology firms, with no revenue generation yet. Negative profit margins and cash flow figures highlight financial challenges, though cash reserves offer short-term stability. The company is heavily reliant on external financing to support its R&D operations.

Income Statement

Intensity Therapeutics has consistently reported zero revenue, indicating a company still in the development phase typical of biotechnology firms. The net profit margins are negative due to ongoing operational expenses without offsetting revenue. EBIT and EBITDA margins are also negative, highlighting the company's high expenditure relative to nonexistent revenue. Revenue and profit growth are absent, reflecting the company's pre-revenue stage.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio due to negative equity, which is typical for companies incurring losses during their R&D phase. Stockholders' equity is negative, indicating liabilities exceed assets. However, cash reserves are sufficient to cover immediate liabilities, which is a positive aspect for liquidity. The equity ratio is not a useful measure here given the negative equity.

Cash Flow

Operating cash flow remains negative, reflecting the cash burn typical for biotech firms in R&D. There is no free cash flow growth due to ongoing operational losses. The financing activities indicate reliance on external funding to support operations. Cash flow ratios are not meaningful due to negative income and free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	-147.00K	0.00	0.00	0.00
EBITDA	-9.22M	-16.27M	-10.09M	-7.50M	-7.88M	-6.03M
Net Income	-11.74M	-16.27M	-10.54M	-7.58M	-7.90M	-5.96M
Balance Sheet
Total Assets	9.59M	4.78M	17.30M	1.76M	5.22M	10.15M
Cash, Cash Equivalents and Short-Term Investments	7.07M	2.59M	14.78M	1.31M	4.54M	9.32M
Total Debt	118.00K	138.00K	158.00K	4.49M	2.34M	497.48K
Total Liabilities	2.36M	1.86M	4.13M	16.86M	13.90M	11.71M
Stockholders Equity	7.22M	2.92M	13.16M	-15.10M	-8.68M	-1.56M
Cash Flow
Free Cash Flow	-9.50M	-15.22M	-7.21M	-5.48M	-6.83M	-5.37M
Operating Cash Flow	-9.50M	-15.22M	-7.21M	-5.48M	-6.83M	-5.37M
Investing Cash Flow	0.00	6.35M	-6.02M	0.00	0.00	4.56M
Financing Cash Flow	13.79M	2.90M	20.47M	2.25M	2.05M	6.29M

Intensity Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.42
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INTS, the sentiment is Positive. The current price of 0.42 is above the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.44, and below the 200-day MA of 0.50, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.07 is Neutral, neither overbought nor oversold. The STOCH value of 65.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INTS.

Intensity Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INTS	45 Neutral	$25.53M	-0.66	-334.12%	―	―	46.41%
SLRX	44 Neutral	$5.23M	-0.02	-139.55%	―	―	68.08%
SCNI	43 Neutral	$818.36K	-0.07	―	―	178.82%	-4121.10%
BDRX	41 Neutral	$1.29M	-0.03	-60.37%	―	-100.00%	86.75%
OGEN	29 Underperform	$3.83M	-0.06	-168.95%	―	―	90.27%

Intensity Therapeutics, Inc. Corporate Events

Intensity Therapeutics Granted Nasdaq Compliance Extension

On December 5, 2025, Intensity Therapeutics, Inc. announced it received a 180-day extension from Nasdaq to comply with the minimum $1.00 bid price requirement, following an initial compliance period that ended on December 3, 2025. The extension allows the company until June 1, 2026, to meet the requirement, with plans to monitor stock prices and consider a reverse stock split if necessary to maintain its Nasdaq listing. This extension does not immediately affect the company’s stock listing, but failure to comply could lead to delisting, impacting stakeholders and market perception.

The most recent analyst rating on (INTS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.

Intensity Therapeutics Expands At-The-Market Offering

On December 4, 2025, Intensity Therapeutics, Inc. announced an increase in the capacity of its ‘at-the-market’ offering program to $30 million, aimed at enhancing financial flexibility. This expansion allows the company to access capital efficiently, though there is no obligation to issue shares, and any utilization will depend on market conditions and strategic priorities.

The most recent analyst rating on (INTS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.

Intensity Therapeutics Enters Securities Purchase Agreement

On October 30, 2025, Intensity Therapeutics, Inc. entered into a Securities Purchase Agreement with an institutional investor to sell 5,000,000 shares of common stock at $0.80 per share, raising approximately $4 million. The offering is expected to close on or around November 3, 2025, and the proceeds will be used for clinical trials, working capital, and general corporate purposes. The company anticipates having sufficient cash until the end of the first quarter of 2027.

The most recent analyst rating on (INTS) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.

Intensity Therapeutics Approves Reverse Stock Split Proposal

On October 22, 2025, Intensity Therapeutics, Inc. held a special meeting of stockholders where approximately 46.61% of the outstanding shares were represented. The stockholders approved a proposal for a reverse stock split of the company’s common stock, with the exact ratio to be determined by the board of directors. Additionally, they approved the potential adjournment of the meeting to allow further solicitation if needed.

The most recent analyst rating on (INTS) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.